Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year? [Yahoo! Finance]
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $4.00 price target on the stock.
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna [Financial Post (Toronto, Ontario, Canada)]
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna